Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho guanine nucleotide exchange factor 1 (ARHGEF1)
- Target
- ARHGEF1
- Molecular classification
- Guanine nucleotide exchange factor (GEF), Signaling protein, RhoGEF family, Other (regulatory cytoskeletal molecule)
01
Overview
Rho guanine nucleotide exchange factor 1 (ARHGEF1) is a cytoplasmic signaling protein that acts as a guanine nucleotide exchange factor (GEF) for the RhoA small GTPase. It mediates signal transduction from G protein-coupled receptors—specifically those signaling through Gα12 and Gα13 subunits—to RhoA, regulating the exchange of GDP for GTP and thereby activating RhoA. Through this mechanism, ARHGEF1 controls key processes involving the actin cytoskeleton, cell adhesion, migration, and contractility. It plays a major role in immune cell localization within lymphoid tissues, vascular smooth muscle cell function, and is implicated in the pathogenesis of cancer (particularly B-cell lymphoma) and cardiovascular disease (such as hypertension). No drugs currently target ARHGEF1 directly, but it remains a significant node in pathways relevant to disease.
- Other names
- p115-RhoGEFp115RhoGEFP115-RHOGEFSUB1.5LBCL2GEF1IMD62LSC115 kDa guanine nucleotide exchange factorLsc homologRhoGEF1
02
Mechanism of action
Activation of RhoA through guanine nucleotide exchange; Modulation of actin cytoskeleton assembly; Mediation of G protein-coupled receptor (GPCR) signal transduction via GNA12 and GNA13 subunit interactions
03
Biological functions
Signal transductionRegulation of actin cytoskeletonCell adhesionCell migrationLymphocyte confinement in lymphoid tissuesRegulation of vascular tone and blood pressure
04
Disease associations
Cancer (e.g., lymphoma)Cardiovascular disease (e.g., hypertension)Neurodegenerative diseaseInflammation
05
Safety considerations
Modulating ARHGEF1 or its pathway can disrupt normal cytoskeletal regulation, potentially affecting immune cell trafficking, vascular tone, and cell proliferation. Therapeutic challenges include broad physiological roles, thus risk of off-target or systemic effects
06
Interacting drugs
None (no direct approved drugs currently target ARHGEF1, but modulators affecting upstream GPCRs or downstream RhoA effectors may impact its signaling)
07
Biomarkers
No direct clinical biomarkers established for ARHGEF1, but loss-of-function or mutation in ARHGEF1 is a research biomarker in B-cell lymphomas
Beyond the preview
Go deeper on Rho guanine nucleotide exchange factor 1 (ARHGEF1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rho guanine nucleotide exchange factor 1 (ARHGEF1).